Clinical trial NCT06636539: Prospective Case Collection Study of Contrast-Enhanced Mammography Imaging Acquired on a New Investigational Device
Official title: Prospective Case Collection Study of Contrast-Enhanced Mammography Imaging Acquired on a New Investigational Device
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Breast Screening
Keywords: CEM
Contrast-Enhanced Mammography
Contrast
Diagnostic mammogram
Mammography
Mammogram
Lead sponsor: Hologic, Inc.
Sponsor class: INDUSTRY
First posted: 2024-10-10
Enrollment: 75
Sex: FEMALE
Minimum age (years): 35
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: This is a prospective, single-center image case collection study to acquire de-identified contrast-enhanced breast images on the Investigational Device to support continuing technology development. Eligible subjects include women at least 35 years old with a suspicious finding or breast abnormality on a screening or diagnostic mammogram who are indicated for a diagnostic exam or a biopsy procedure.

Detailed description: Contrast-Enhanced Mammography (CEM) is intended to be an extension for diagnostic mammography with the Investigational Device. It is a technique in which digital 2D mammography is supplemented with the use of intravenous iodinated contrast administration to facilitate cancer detection. The imaging acquired under a contrast agent has preferential uptake in regions of increased vascularity providing complement information for diagnosis. The CEM software application that will be tested is similar to the marketed software I-View™ 2.0 and is intended for use as an adjunct following mammography and/or ultrasound exams as a diagnostic work-up to localize and further characterize a known or suspected lesion.

Thus, to assess the clinical efficacy of the CEM imaging acquired in the Investigational Device, Sponsor is conducting a prospective case collection study to support the verification and validation of image quality assessments.

Eligibility criteria: Inclusion Criteria:

* Subject is female of any race and ethnicity.
* Subject is at least 35 years old
* Subject has a suspicious finding or breast abnormality on a screening or diagnostic mammogram and is indicated for a diagnostic exam or a biopsy procedure.
* Subject is able to read, understand, and sign the study-specific informed consent form (ICF) after the nature of the study has been fully explained to them

Exclusion Criteria:

* Subject is unable or unwilling to undergo informed consent or subject who requires a Legally Authorized Representative (LAR) for Informed Consent.
* Subject has breast implants, cardiac pacemakers, nipple piercings, or IV ports in the mammography field of view in the breast of interest.
* Subject has had an interventional procedure in the same breast as the suspicious finding within the last six (6) months
* Subject is pregnant or presumed to be pregnant.
* Subject is breastfeeding.
* Subject is actively being treated for cancer of any type with chemotherapy
* Subject is suspected to be at risk of complications from the iodinated contrast agent. These include contra-indications of standard iodinated contrast agents, such as the subject having renal insufficiency) and the subject being on dialysis.
* Subject has had a prior reaction to iodinated contrast; thus, a known allergy to iodinated contrast.
* Subject has had a prior reaction to gadolinium contrast agents; thus, a known allergy to gadolinium contrast.
* Subject who, based on the physician's judgment, may be at increased risk for complications associated with renal function, anticoagulant therapy, or bleeding disorders.

Primary outcomes:
measure: Obtain de-identified contrast-enhanced breast images on the Investigational Device.
timeFrame: 4 months
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: Solis Mammography Memorial Village
state: Texas
Study officials:
affiliation: Solis Mammography
name: Chirag Parghi, MD
role: PRINCIPAL_INVESTIGATOR
References: